Interferon β-1b and glatiramer acetate effects on permanent black hole evolution

Area of Science:

• Neurology
• Immunology
• Radiology

Background:

• Relapsing-remitting multiple sclerosis (RRMS) involves irreversible tissue damage, often visualized as permanent black holes (PBH) on MRI.
• Comparing the efficacy of disease-modifying therapies like interferon beta-1b (IFNβ-1b) and glatiramer acetate (GA) is crucial for managing RRMS.
• PBH evolution from new lesions (NL) serves as a key indicator of disease progression and treatment effectiveness.

Purpose of the Study:

• To compare the development of PBH from new lesions (NL) between patients treated with IFNβ-1b and GA in RRMS.
• To assess the impact of IFNβ-1b (250 μg and 500 μg) versus GA on irreversible brain tissue damage markers.

Main Methods:

• The BEYOND trial, a Phase III clinical study, compared IFNβ-1b (250 μg and 500 μg) against GA (2:2:1 ratio).
• MRI scans were analyzed post hoc by blinded raters to quantify PBH formation and evolution from year 1 NL to year 2.
• Primary endpoints focused on the number and proportion of NL evolving into PBH at year 2 when comparing IFNβ-1b 250 μg to GA.

Main Results:

• Fewer PBH per patient evolved from year 1 NL at year 2 for IFNβ-1b 250 μg compared to GA (0.30 vs 0.43; p=0.0451).
• The exploratory comparison showed significantly lower PBH numbers (0.26 vs 0.43; p=0.0037) and a lower proportion of NL evolving into PBH (16.3% vs 23.5%; p=0.0409) for IFNβ-1b 500 μg versus GA.
• The proportion of NL evolving into PBH was not significantly different between IFNβ-1b 250 μg and GA (21.6% vs 23.5%; p>0.20).

Conclusions:

• Interferon beta-1b demonstrated comparable or superior effects to glatiramer acetate in mitigating PBH development.
• IFNβ-1b favorably influences MRI outcomes associated with permanent tissue destruction in MS patients.
• The findings suggest IFNβ-1b may offer a greater neuroprotective benefit in managing RRMS.